Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Technically Resectable Hepatocellular Carcinoma

NCT04930315 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT04930315
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04930315 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Technically Resectable Hepatocellular Carcinoma
Lead sponsor
Zhejiang University
Phase
Phase 2
Overall status
Completed
Start date
September 15, 2021
Completion date
April 30, 2026
Enrollment
78 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma